Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1982 1
1983 3
1984 1
1986 1
1987 2
1988 4
1989 4
1990 4
1991 4
1992 4
1993 8
1994 3
1995 3
1996 4
1997 6
1998 8
1999 4
2000 6
2001 6
2002 7
2003 3
2004 2
2005 1
2006 3
2007 8
2008 7
2009 6
2010 4
2011 5
2012 5
2013 6
2014 5
2015 8
2016 8
2017 8
2018 3
2019 7
2020 7
2021 18
2022 13
2023 11
2024 8

Text availability

Article attribute

Article type

Publication date

Search Results

215 results

Results by year

Filters applied: . Clear all
Page 1
Inhibiting the MNK1/2-eIF4E axis impairs melanoma phenotype switching and potentiates antitumor immune responses.
Huang F, Gonçalves C, Bartish M, Rémy-Sarrazin J, Issa ME, Cordeiro B, Guo Q, Emond A, Attias M, Yang W, Plourde D, Su J, Gimeno MG, Zhan Y, Galán A, Rzymski T, Mazan M, Masiejczyk M, Faber J, Khoury E, Benoit A, Gagnon N, Dankort D, Journe F, Ghanem GE, Krawczyk CM, Saragovi HU, Piccirillo CA, Sonenberg N, Topisirovic I, Rudd CE, Miller WH Jr, Del Rincón SV. Huang F, et al. Among authors: ghanem ge. J Clin Invest. 2024 May 1;134(9):e181575. doi: 10.1172/JCI181575. J Clin Invest. 2024. PMID: 38690739 Free PMC article. No abstract available.
MNK1/2 inhibition limits oncogenicity and metastasis of KIT-mutant melanoma.
Zhan Y, Guo J, Yang W, Goncalves C, Rzymski T, Dreas A, Żyłkiewicz E, Mikulski M, Brzózka K, Golas A, Kong Y, Ma M, Huang F, Huor B, Guo Q, da Silva SD, Torres J, Cai Y, Topisirovic I, Su J, Bijian K, Alaoui-Jamali MA, Huang S, Journe F, Ghanem GE, Miller WH Jr, Del Rincón SV. Zhan Y, et al. Among authors: ghanem ge. J Clin Invest. 2024 Apr 15;134(8):e181338. doi: 10.1172/JCI181338. J Clin Invest. 2024. PMID: 38618965 Free PMC article. No abstract available.
P2Y12 Inhibition in Patients Requiring Oral Anticoagulation after Percutaneous Coronary Intervention: The SWAP-AC-2 Study.
Ortega-Paz L, Bor W, Franchi F, van de Broek WWA, Rollini F, Giordano S, Galli M, Been L, Ghanem G, Shalhoub A, Garabedian H, Al Saleh T, Uzunoglu E, Zhou X, Rivas A, Pineda AM, Suryadevara S, Soffer D, Mahowald MK, Choi CY, Zenni MM, Phoenix F, Ajjan RA, Ten Berg JM, Angiolillo DJ. Ortega-Paz L, et al. Among authors: ghanem g. JACC Cardiovasc Interv. 2024 Apr 1:S1936-8798(24)00631-9. doi: 10.1016/j.jcin.2024.03.027. Online ahead of print. JACC Cardiovasc Interv. 2024. PMID: 38597172
Switching From Cangrelor to Prasugrel in Patients Undergoing Percutaneous Coronary Intervention: The Switching Antiplatelet-6 (SWAP-6) Study.
Franchi F, Rollini F, Ortega-Paz L, Been L, Giordano S, Galli M, Ghanem G, Garabedian H, Al Saleh T, Uzunoglu E, Rivas A, Pineda AM, Suryadevara S, Soffer D, Zenni MM, Mahowald M, Reiter B, Jilma B, Angiolillo DJ. Franchi F, et al. Among authors: ghanem g. JACC Cardiovasc Interv. 2023 Oct 23;16(20):2528-2539. doi: 10.1016/j.jcin.2023.08.009. Epub 2023 Aug 21. JACC Cardiovasc Interv. 2023. PMID: 37609698 Clinical Trial.
215 results